Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab

This study is testing a combination of three drugs — TUDCA (a bile acid supplement), camrelizumab (an immunotherapy drug), and regorafenib (a targeted therapy) — for people with advanced liver cancer (hepatocellular carcinoma) that got worse after prior treatment with immunotherapy plus bevacizumab. **You may be eligible if...** - You are 18 or older - You have confirmed advanced liver cancer that cannot be surgically removed - Your cancer progressed after treatment with a PD-1/PD-L1 inhibitor plus bevacizumab - You have at least one measurable tumor - Your liver is functioning reasonably well (Child-Pugh 5–7) - If you have hepatitis B, your viral load is under control with antiviral medication - Your life expectancy is at least 12 weeks **You may NOT be eligible if...** - You have had a liver transplant or are on a waiting list - You have significant heart disease or history of serious bleeding in the past 4 weeks - You have had a stroke, deep vein clot, or pulmonary embolism in the past 6 months - You have active HIV - You are pregnant or breastfeeding - You have active autoimmune disease requiring systemic treatment - You have interstitial lung disease (lung scarring) Talk to your doctor to see if this trial is right for you.